Business Wire

COPD: New Data Support Role of Spiolto® Respimat® as 1st-line Maintenance Therapy and Show Superiority over LABA/ICS

28.9.2015 12:00 | Business Wire

Del

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A post-hoc analysis from OTEMTO® 1&2 indicates that Spiolto® Respimat® provides significant quality of life improvements over Spiriva® Respimat® (tiotropium) or placebo, right from the initial stage when patients first need maintenance therapy.1 These data support the role of Spiolto® Respimat® as a new 1st line maintenance therapy for COPD. In addition the ENERGITO® study shows that the lung function improvement§ with Spiolto® Respimat® (tiotropium/olodaterol) is superior to a steroid-containing therapy (LABA/ICS FDC) in patients with moderate to severe COPD.2

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150928005716/en/

(Photo: Business Wire)

(Photo: Business Wire)

From early in the course of COPD, decreasing lung function makes it more and more difficult for people to breathe. To cope with feeling breathless, patients reduce their activity and change their lifestyles which can lead to a ‘downward spiral’ of their condition.3 This in turn results in a large physical and emotional impact on people living with the disease.4 Providing optimal treatment right from the start of maintenance therapy can give patients the best chance of managing their symptoms, keeping active and maintaining their quality of life.

“These two trials further characterise the relevant benefits Spiolto® Respimat® provides compared to two commonly prescribed maintenance treatments: Spiriva® Respimat® and a LABA/ICS FDC,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “The lung function and quality of life improvements shown in these trials add to the growing body of evidence supporting the benefit of using Spiolto® Respimat® at the initiation of maintenance therapy for COPD.”

OTEMTO ® 1&2 - data reinforce Spiolto ® Respimat ® benefits as 1 st -line maintenance therapy

A post-hoc analysis of the OTEMTO® 1&2 trials* (NCT01964352/ NCT02006732), presented at ERS for the first time, shows that Spiolto® Respimat® provides a clinically meaningful 4 point improvement in quality of life§§ compared to placebo in COPD patients with GOLD 2 disease.1 In the same patient group, 13% more patients achieved a clinically meaningful improvement in quality of life with Spiolto® Respimat® compared to Spiriva® Respimat® (52.8% compared to 39.2%).5

“With no cure for COPD, improving quality of life is one of the major goals of treatment,” said Dave Singh, Professor of clinical pharmacology and respiratory medicine, University of Manchester. “When many patients are first diagnosed their condition is already declining rapidly. Doing as much as possible, early on, can give patients the best opportunity to maintain a good quality of life for longer. This sub-analysis shows that Spiolto® Respimat® could give patients this opportunity.”

These latest results add to the recently published OTEMTO® 1&2 data in Respiratory Medicine, 6 which show Spiolto® Respimat® provides consistent improvements in lung function, breathlessness and quality of life over Spiriva® Respimat® (tiotropium) or placebo. The data also shows that Spiolto® Respimat® provides a safety profile similar to Spiriva® Respimat® or placebo. Incidence of adverse events (AEs) was broadly similar across treatment groups, with a higher incidence of AEs leading to discontinuation in the placebo groups compared to the treatment groups.6

ENERGITO ® - superior lung function improvements over LABA/ICS FDC

Also presented for the first time, data from ENERGITO® (NCT01969721) show that Spiolto® Respimat® met all lung function endpoints**, which included a 42% improvement in trough FEV1, compared to the twice daily LABA/ICS salmeterol/fluticasone propionate in patients with moderate to severe COPD.2

ICS, or steroid-containing therapies, can be associated with potential serious side-effects and guidelines only recommend the use of these treatments in patients with severe COPD and frequent exacerbations (more than 2 per year).7 Despite this, in clinical practice ICS-based therapies are widely used across all COPD stages even for patients with low exacerbation risk who have less severe COPD. In this respect, the results from ENERGITO® add to data from the large-scale WISDOM study,8 raising questions about whether the benefits of ICS outweigh the potential side-effects associated with this class of treatment.

“ICS-containing therapies certainly have a role in the management of COPD but questions remain regarding when to use these treatments,” said Professor Kai-Michael Beeh, Insaf GmbH Institut für Atemwegs-forschung, Wiesbaden, Germany. “The ENERGITO® results further support the potential benefit of Spiolto® Respimat® as a COPD maintenance therapy and the notion that steroid-containing therapies may only be required in a population of patients with more severe stages of the disease and frequent exacerbations.”

The OTEMTO® 1&2 and ENERGITO® trials are part of the >15,000 patient TOviTO® Phase III clinical trial programme investigating the efficacy and safety of Spiolto® Respimat® in COPD. The results build on the pivotal phase III TONADO® trials that demonstrated Spiolto® Respimat® provides significant improvements in lung function, breathlessness, quality of life and reduction in rescue medication use over Spiriva® Respimat® right from the initial disease stages when patients first need maintenance therapy.9,10 Data also showed that Spiolto® Respimat® was well tolerated with a favourable safety profile that was similar to tiotropium or olodaterol alone.9

For ‘Notes to Editors’ and ‘References’ please visit: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/28_september_2015_copd.html

_______________________

* Results are derived from a post-hoc subgroup analysis of patients with moderate COPD (GOLD stage 2). The primary endpoints of the OTEMTO® studies were: FEV1 AUC0-3, trough FEV1, SGRQ total score in patients with moderate to severe COPD (GOLD stage 2–3)

Chronic obstructive pulmonary disease

§ FEV1 AUC0-12 response (primary endpoint), FEV1 AUC0-24, FEV1 AUC12-24 and trough FEV1 (secondary endpoint), all measured at 6 weeks

‡ long acting beta2 agonist/inhaled corticosteroid fixed dose combination (FDC)

§§ As measured by the St George’s Respiratory Questionnaire (SGRQ)

** FEV1 AUC0-12 response (primary endpoint), FEV1 AUC0-24, FEV1 AUC12-24 and trough FEV1 (secondary endpoint), all measured at 6 weeks

 

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr Kristin Jakobs
Phone: +49 6132 77 144553
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Altierre Strengthens Executive Team in Europe With Hiring of Guillaume Vicot and Niclas Qvist22.8.2017 12:00Pressemelding

Altierre Corp., a provider of the world’s highest density, ultra-low energy, long-range wireless technology and applications for the Internet of Things (IoT) market, today announced two additions to its France-based European executive team. Guillaume Vicot has joined the company as General manager, Europe, Middle East and Asia (EMEA) and Niclas Qvist has joined as Vice President, Partner management & Marketing. Vicot joins Altierre’s management team after 17 successful years in the Auto-ID industry, barcode scanning and mobile computing. He most recently served as Vice President of sales, Western Europe, for PSC / Datalogic, leader in the bar code scanning industry, where he oversaw a team of more than 100 people and developed a tactical go-to-market strategy, achieving revenue well over US$100 million. “Guillaume has many top level strategic relationships with retailers

IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 20:15Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati

Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 20:11Pressemelding

Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom